GeneDx Holdings Reports Better-Than-Expected Q2 Earnings and Revenue
GeneDx Holdings (WGS) reported second-quarter GAAP earnings per share of -$0.60, which exceeded the expected loss by $0.11. The company also generated revenue of $114.4 million in the quarter, a 11.4% increase year-over-year and surpassing estimates by $3.39 million. The firm reaffirmed its full-year 2026 revenue guidance between $475 million to $490 million, aligning with market expectations of around $478.38 million. The growth is attributed to increased exome and genome testing volumes expected to rise by at least 30%. The results reflect strong performance in the healthcare diagnostics sector despite ongoing challenges for small-cap stocks.
Tickers: $WGS